India Glycols Posts Strong Q1 FY27 Results Amidst Demerger

India Glycols' Q1 FY27 consolidated net revenue reached INR 1,130 crore, marking a 9% year-on-year increase. The company's EBITDA saw a healthy rise of 13% to INR 170 crore.

Reader Takeaway: Strong revenue growth and successful demerger sanctioning offer positive outlook, but volatile costs pose a challenge.

What just happened

India Glycols reported robust financial performance for the first quarter of FY27. Consolidated net revenue stood at INR 1,130 crore, a 9% increase compared to the same period last fiscal. EBITDA grew by 13% to INR 170 crore. Finance costs were significantly reduced to INR 25 crore from INR 45 crore in the prior year, attributed to debt reduction efforts.

The National Company Law Tribunal (NCLT) sanctioned the company's scheme of arrangement on July 17, 2026. This paves the way for the segregation of India Glycols into three distinct listed entities.

Why this matters

The strong revenue and EBITDA growth indicate operational efficiency and market demand for India Glycols' products. The demerger, once effective, is expected to unlock value by creating focused businesses with clearer strategic direction. The company's stated aspiration to become debt-free from FY28 onwards is a significant long-term financial goal for shareholders.

The backstory

India Glycols has been strategically focusing on enhancing its spirits business, including bio-fuel, and expanding its chemical and biopharma segments. The decision to demerge aims to streamline operations and allow each business vertical to pursue its growth trajectory independently.

What changes now

Upon the demerger's effectiveness, the company will split into:

• IGL Spirits Limited (potable spirits and bio-fuel)
• Ennature Bio Pharma (nutraceuticals, APIs, biopolymers)
• India Glycols Limited (bio-based chemicals, glycols, performance chemicals, gases).

This structural change aims to provide better focus and potentially attract differentiated valuations for each entity.

Risks to watch

Management highlighted concerns regarding raw material price volatility, particularly crude oil, and significant spikes in freight costs, which have impacted the chemical business's margins. Disruptions in international shipments to the Middle East and the US also presented headwinds for the performance chemicals segment. The company acknowledges execution risk in achieving its long-term aspirations.

Peer comparison

While specific peer data for Q1 FY27 was not provided in the filing, the spirits segment's revenue growth of 5.3% and volume surge of 55% in IMFL are strong indicators. The chemicals segment's 20.6% revenue increase suggests it is performing competitively, though margin pressures due to external factors are a concern across the industry.

Context metrics (time-bound)

• Q1 FY27 Net Revenue: INR 1,130 crore (up 9% YoY)
• Q1 FY27 EBITDA: INR 170 crore (up 13% YoY)
• Q1 FY27 Finance Costs: INR 25 crore (down from INR 45 crore YoY)
• IMFL Volume Growth: 55% (1.4 million cases)

What to track next

Investors will be keenly watching the effective date of the demerger and the subsequent performance of the three newly formed entities. The company's ability to navigate volatile commodity prices and freight costs, while executing its premiumization strategy in spirits and specialty chemicals, will be crucial.